Table II. Description of the studied Cameroonian SCD cohort.
| Variable | Median (25th- 75th percentiles) or % | Range | Observations (n) | |
|---|---|---|---|---|
| Age (years) | 16 (9-24) | 5-54 | 436 | |
| Gender | Female/Male (219/216) | - | 436 | |
| Haematological indices | RBC (x1012/l) | 2.7 (2.3-3.1) | 1.4 -5.5 | 436 |
| Hb (g/l) | 76 (67-85) | 35-145 | 436 | |
| MCV (fl) | 84 (78-91) | 59.0-117.0 | 436 | |
| MCHC (g/l) | 338 (316-358) | 215-529 | 436 | |
| WBC (× 109/l) | 12.8(9.1-16.2) | 2.9-49.8 | 436 | |
| Lymphocytes (× 109/l) | 5.2 (4.0-7.2) | 0.2-22.6 | 436 | |
| Monocytes (× 109/l) | 1.3 (0.9-1.8) | 011-7.8 | 436 | |
| Platelet count (× 109/l) | 374.3 (291.2-448.0) | 97-756 | 436 | |
| HbA2 (%) | 3.6 (3.0-4.2) | 0-18.2 | 436 | |
| HbF (%) | 8.8 (2.5-14.1) | 0-37.4 | 436 | |
| Clinical events | VOC (n/year) | 2 (1-4) | 0-40 | 436 |
| Consultations (n/year) | 2 (0-4) | 0-24 | 324 | |
| Hospitalisation (n/year) | 1 (0-2) | 0-30 | 422 | |
| Blood transfusion (%) | 77.8 | 330/424 | ||
| Stroke (%) | 3.9 | 17/436 | ||
| 3.7 HBA1/HBA2 deletion genotypes | αα / αα | 59.8 | 225/376 a | |
| αα/ α3.7 | 30.1 | 113/376 a | ||
| α 3.7/α 3.7 | 10.1 | 38/376 a | ||
| HBB Haplotype | Benin/Benin | 64.1% | 212/331 a | |
| Benin/Cameroon | 30.8% | 102/331 a | ||
| Cameroon/Cameroon | 5.1% | 17/331 a | ||
| Renal functions£ | Crude albuminuria (mg/l) | 41 (23-83) | 3-1180 | 407 |
| eGFR (CKD-EPI) (ml/min/1.73m2) | 135.1 (112.0-154.4) | 50.8-250.8 | 404 | |
| Serum creatinine (μmol/l) | 7 (5-8.5) | 2-13.8 | 404 | |
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFR: estimated glomerular filtration rate; Hb: haemoglobin; MCHC: mean corpuscular haemoglobin concentration; MCV: mean corpuscular volume; RBC: red blood cell count; SCD: sickle cell disease; VOC: vaso-occlusive crises; WBC: white blood cell count.
a
Number of individuals, not alleles;
£
previously reported in Geard et al (2017).